市場調查報告書
商品編碼
949666

全球肥厚性心肌病(HCM)治療市場:2020-2026

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計在預測期內,全球肥厚型心肌病(HCM)治療市場將緩慢增長。對心臟病的認識不斷提高,為市場增長做出了貢獻。政府努力提高人們對CVD健康的認識,導致心肌病的診斷和治療增加。為了提高人們對CVD預防和控制的認識,已經啟動了一些認識計劃。例如,2004年,美國心臟協會發起了一項國際宣傳運動,名為"為婦女變紅"運動,以預防,診斷和管理女性的CVD。這些類型的計劃提高了人們對心肌病的認識,並導致了CVD的早期診斷。反過來,這有望增加對HCM藥物治療的需求,以降低心臟可以改善血液流動的心率。然而,對心臟手術的新需求在很大程度上限制了市場的增長。

在地理上,由於CVD患病率增加以及政府對預防,診斷和治療醫療狀況的興趣增加,預計亞太地區在預測期內將顯示出顯著增長。我是。 HCM是最常見的遺傳性心臟病,在包括中國和印度在內的亞太國家中,其患病率呈上升趨勢。它促進了對藥物的需求,以控制症狀和預防猝死。

本報告調查了全球肥厚型心肌病(HCM)治療市場,提供了該市場的概述,按藥物類別和地區劃分的趨勢以及進入該市場的公司的概況。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢
  • 規則和規定

第3章競爭情況

  • 公司份額分析
  • 主要策略分析
  • 主要公司分析
    • 阿斯利康
    • ANI Pharmaceuticals,Inc.
    • MyoKardia,Inc.
    • 拜耳公司
    • Sanofi S.A.

第4章市場決定因素

  • 動機
  • 抑制因子
  • 市場機會

第5章市場細分

  • 按藥物分類的全球肥大性心肌病(HCM)治療市場
    • beta腎上腺素能阻滯劑
    • 抗凝劑
    • 抗心律失常藥
    • 鈣通道阻滯劑
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章公司簡介

  • A. Menarini Farmaceutica Internazionale srl
  • ANI Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Cipla Ltd.
  • General Electric Co.
  • Gilead Sciences, Inc.
  • Lannett Co., Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • MyoKardia, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
目錄
Product Code: OMR2021985

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size, Share & Trends Analysis Report, By Drug Class (Beta Adrenergic Blocking Agents, Anticoagulants, Antiarrhythmic Agents, Calcium Channel Blockers, and Others) and Forecast, 2020-2026

The global hypertrophic cardiomyopathy (HCM) therapeutics market is expected to witness sluggish growth during the forecast period. Rising awareness regarding heart diseases is contributing to market growth. The government initiatives to increase awareness regarding CVD health is leading to an increasing diagnosis and treatment of the condition. There are several awareness programs launched to make aware people regarding prevention and control of CVD. For instance, in 2004, the American Heart Association launched an international awareness campaign, referred to as Go Red for Women campaign, for the prevention, diagnosis and control of CVD in women. These kinds of initiatives enable to increase awareness about the conditions, leading to an early diagnosis of CVD. This, in turn, is expected to drive the demand for HCM medications to decrease heart rate that enables the heart to pump blood better. However, emerging demand for cardiac surgeries is primarily restricting the growth of the market.

Geographically, Asia-Pacific is estimated to witness significant growth during the forecast period owing to the increasing prevalence of CVD and increasing government focus towards prevention, diagnosis, and treatment of the condition. HCM is the most common inherited cardiac disease that has been witnessing increasing prevalence in Asia-Pacific countries, including China and India. This, in turn, will encourage the demand for medications to control symptoms and prevent sudden death.

Key players in the market include AstraZeneca plc, ANI Pharmaceuticals, Inc., MyoKardia, Inc., Bayer AG, and Sanofi S.A. ANI Pharmaceuticals offers InnoPran XL, Inderal LA, and Inderal XL, that are used for the treatment of HCM. InnoPran XL is a class of medications referred to as beta-adrenergic blocker, designed to treat hypertension, to lower blood pressure. The reduction in blood pressure minimizes the risk of fatal and non-fatal CVD events, particularly myocardial infarction and strokes. Further, MyoKardia, Inc., mavacamten is in Phase II for the treatment of obstructive HCM.

Research Methodology

The market study of the global HCM therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global HCM Therapeutics Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global HCM therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global HCM therapeutics market.
  • Insights about market determinants, which are stimulating the global HCM therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca plc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. ANI Pharmaceuticals, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. MyoKardia, Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Bayer AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sanofi S.A.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global HCM Therapeutics Market by Drug Class
    • 5.1.1. Beta Adrenergic Blocking Agents
    • 5.1.2. Anticoagulants
    • 5.1.3. Antiarrhythmic Agents
    • 5.1.4. Calcium Channel Blockers
    • 5.1.5. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. A. Menarini Farmaceutica Internazionale srl
  • 7.2. ANI Pharmaceuticals, Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Bristol Myers Squibb Co.
  • 7.6. Cipla Ltd.
  • 7.7. General Electric Co.
  • 7.8. Gilead Sciences, Inc.
  • 7.9. Lannett Co., Inc.
  • 7.10. Merck & Co., Inc.
  • 7.11. Mylan N.V.
  • 7.12. MyoKardia, Inc.
  • 7.13. Novartis International AG
  • 7.14. Pfizer Inc.
  • 7.15. Sanofi S.A.

LIST OF TABLES

  • 1. GLOBAL HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 2. GLOBAL BETA-ADRENERGIC BLOCKING AGENTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ANTICOAGULANTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL ANTIARRHYTHMIC AGENTS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL CALCIUM CHANNEL BLOCKERS FOR HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER HCM THERAPEUTICS DRUG CLASSES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 8. NORTH AMERICAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 9. NORTH AMERICAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 10. EUROPEAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 11. EUROPEAN HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 12. ASIA-PACIFIC HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. ASIA-PACIFIC HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)
  • 14. REST OF THE WORLD HCM THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HCM THERAPEUTICS MARKET SHARE BY DRUG CLASS, 2019 VS 2026 (%)
  • 2. GLOBAL HCM THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 3. US HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 4. CANADA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. UK HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. FRANCE HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. GERMANY HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. ITALY HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. SPAIN HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ROE HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. INDIA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. CHINA HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. JAPAN HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF THE WORLD HCM THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)